| Literature DB >> 32898940 |
Jeong-Seon Lee1, Hye Young Jin2, Jung Min Ko1, Seoung Hoon Kim3, Nayoung Han4, Byung Kiu Park2, Meerim Park2, Hyeon Jin Park2, Jun Ah Lee2.
Abstract
Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare liver cancer affecting adolescents and young adults without any pre existing liver disease. Hyperammonemic encephalopathy (HAE) is a serious paraneoplastic syndrome, and several cases of HAE have been reported in patients with FLHCC. This condition is rare; hence, there are currently no management guidelines for cancer-related HAE. Herein, we report a case of an 18-year-old man with advanced FLHCC who developed HAE during the first course of chemotherapy consisting of cisplatin, doxorubicin, 5-fluorouracil, and interferon-α. He was successfully treated with continuous venovenous hemofiltration, sodium benzoate, sodium phenylbutyrate, and amino acid supplementation for HAE. After the second course of chemotherapy, he underwent surgery, and thereafter, his ammonia levels were normal without any ammonia scavenger therapy. Treatments for HAE described here will be helpful for this rare, but serious metabolic complication of FLHCC and could partially applied to HAE related to any malignancies.Entities:
Keywords: Encephalopathy; Fibrolamellar hepatocellular carcinoma; Hyperammonemia; OTC deficiency
Year: 2020 PMID: 32898940 DOI: 10.4143/crt.2020.575
Source DB: PubMed Journal: Cancer Res Treat ISSN: 1598-2998 Impact factor: 4.679